论文部分内容阅读
将16例恶性血液病患者随机分为A组和B组,A组第1周期化疗结束后使用重组人白细胞介素-11(rhIL-11)(A周期)皮下注射,剂量40ug/(kg·d),连用10d。第2疗程化疗结束后观察为空白对照(B周期);B组则相反,第1疗程化疗不使用rhIL-11(B周期),第2疗程化疗联合使用rhIL-11(A周期)。观察rhIL-11的疗效和毒副作用。A周期的血小板(PLT)最高值及化疗第21d的PLT值明显高于B周期,PLT低于50×109/L的持续时间:rhIL-11治疗组平均为(1.0±2.0)d,对照组为(6.9±5.3)d。表明rhIL-11具有升高化疗后PLT的作用,促进因化疗骨髓抑制所致的血小板减少的恢复,不良反应轻微,值得临床广泛应用。
Sixteen patients with hematologic malignancies were randomly divided into group A and group B. Subcutaneous injection of recombinant human interleukin-11 (A cycle) at the end of the first cycle of group A was administered at a dose of 40 ug / (kg · d), used in conjunction with 10d. The second course of chemotherapy was observed after the blank control (B cycles); B group is the opposite, the first course of chemotherapy does not use rhIL-11 (B cycles), the first two cycles of chemotherapy combined with rhIL-11 (A cycle). Observe the efficacy and toxicity of rhIL-11. The highest value of platelet (PLT) in A cycle and the PLT value at 21 d after chemotherapy were significantly higher than those in B cycle. The duration of PLT less than 50 × 109 / L was (1.0 ± 2.0) days in rhIL-11 group, (6.9 ± 5.3) d. It is indicated that rhIL-11 has the effect of increasing PLT after chemotherapy and promoting the recovery of thrombocytopenia due to chemotherapy myelosuppression with mild adverse reactions, which is worth to be widely used clinically.